Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Zishen Qinggan
- Development stage
- Unknown
- Lead developer
- Children's Hospital of Fudan University
- Administration
- Oral
01
Overview
Zishen Qinggan (ZSQG) is a Traditional Chinese Medicine (TCM) polyherbal granule formula developed by the Children's Hospital of Fudan University for the treatment of partial or mild true precocious puberty (PPP) in girls. As a multi-component botanical medicine, it is designed to address TCM syndrome patterns associated with early pubertal development. In clinical studies, ZSQG has been evaluated for its ability to reduce mammary nucleus size and improve Chinese medicine syndrome scores. It is administered orally as granules, typically three times daily for a duration of six months.
- Other names
- Zishen Qinggan granules
Beyond the preview
Go deeper on Zishen Qinggan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Zishen Qinggan.